PT-141: what it is, what it costs, and who sells it

PT-141 is bremelanotide, a melanocortin receptor (MCR) agonist. Its FDA-approved branded product, Vyleesi (NDA 210557), was approved June 21, 2019 for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women — the label states plainly it is “not indicated for the treatment of HSDD in postmenopausal women or in men.” Vyleesi ships as a pre-filled, ready-to-use 1.75 mg/0.3 mL autoinjector, with no reconstitution step at all.

Compounded PT-141 is a genuinely different product: sterile lyophilized powder in a vial that the buyer reconstitutes with bacteriostatic water, sold widely off-label — including to men — despite Vyleesi's own approval never covering that use. It is not reviewed by FDA at the dose accuracy, sterility, or purity level Vyleesi's autoinjector was, and it is what nearly every provider on the board below sells.

Bremelanotide activates melanocortin receptors — chiefly MC4R, concentrated in the hypothalamus, where it is understood to trigger dopamine release that increases sexual desire, a brain-mediated mechanism categorically distinct from PDE5 inhibitors (sildenafil-class), which act peripherally on blood flow rather than desire itself. The same receptor family includes MC1R, active on melanocytes — the direct mechanistic reason Vyleesi's label carries a hyperpigmentation warning, not an unrelated side effect. Read the full RECONNECT Phase 3 trial results and what they do and don't show outside the approved population in our full PT-141 evidence review.

Vyleesi itself is FDA-approved and legally prescribed for its narrow indication. The compounded, reconstituted PT-141 powder most sellers actually offer is a different product FDA has never reviewed — sold under the general 503A/503B compounding framework, not the shortage-specific exception tirzepatide and semaglutide are compounded under, since Vyleesi has never been in an FDA-declared shortage.

Evidence for male use traces back to a discontinued mid-2000s intranasal program — never approved, reportedly halted after Phase 3 trials showed dose-dependent blood pressure elevations — plus a still-active but not-yet-reported Palatin program testing a different, co-formulated injectable product. Neither supports a completed, published, placebo-controlled efficacy claim for the plain compounded powder sold today. See our evidence review for the full history.

Vyleesi's label reports nausea in 40% of treated patients, severe enough to require anti-emetic therapy in 13% and to end treatment for 8%. Focal hyperpigmentation — dark patches on the face, gums, or breasts — occurred in 1% of Phase 3 patients and is not confirmed to fully reverse in all cases after stopping. The drug also transiently raises blood pressure and lowers heart rate after each dose, and is contraindicated in uncontrolled hypertension or known cardiovascular disease.

These warnings describe what bremelanotide the molecule does in the body, not a quirk of the autoinjector — there is no mechanistic reason to expect a reconstituted, compounded version of the same molecule to be exempt from any of them. For the exact numbers behind Vyleesi's full adverse-reaction table, see our PT-141 dosage and side-effects review. None of this is a recommendation for or against PT-141 — talk to a licensed clinician about your own situation.